AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04709601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hiprex
Description: Patients with negative urine culture will be prescribed Hiprex 1 g PO BID x 1 yr and patients with a positive urine culture will be prescribed antibiotics.
Study NCT05666310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Half of study participants will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 with zoledronic acid placebo at month 0.
Study NCT05666310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Half of study participants will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 with denosumab placebo at month 0 and 6. All forty participants will receive zoledronic acid 5 mg intravenous infusion at month 12.
Study NCT05666310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab Placebo
Description: Half of study participants who will randomly receive zoledronic acid 5 mg intravenous infusion at month 0 will also receive denosumab placebo at month 0 and 6.
Study NCT05666310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid Placebo
Description: Half of study participants who will randomly receive denosumab 60 mg subcutaneous injection at month 0 and 6 will also receive zoledronic acid placebo.
Study NCT05024929 — intervention group
Intervention type: PROCEDURE
Intervention: Whole body scan
Description: Patients will receive oncogene-specific molecularly targeted therapy independently of this protocol either via commercial supply of an FDA approved agent, or as part of a separate therapeutic clinical trial/compassionate use protocol/single patient investigational new drug (IND).~During screening, patients will undergo a baseline RAI-whole body scan (WBS) to assess RAI-avidity of their tumor per standard of care. Following approximately 28 days of targeted therapy, the WBS will be repeated to determine whether this therapy is associated with an increase in RAI-avidity of their tumor.
Study NCT06494683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pueraria lobata radix
Description: The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
Study NCT06494683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pueraria lobata radix
Description: The dose of Pueraria lobata radix granules is one sachet per day, 1.5g per sachet, which equivalent to 15 g of the original herb.
Study NCT04258345 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ASB Feeding Study
Description: Participants will undergo a washout period and then scheduled for blood draw after which ASB feeding period will begin followed by a second blood draw.
Study NCT05356455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interview technique
Description: Difference between pre-test and post-test
Study NCT05930431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity variety intervention
Description: The counseling in the variety condition will serve many purposes. The first session will concentrate on informing participants on the importance of having variety in their physical activity routine and how to access the variety of physical activities available to them. The variety condition will be instructed to complete at least three different HIIT workouts per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting variety in physical activity but also to support participants' basic psychological needs.
Study NCT05930431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity consistency comparison condition
Description: The counseling in the consistency condition will serve many purposes. The first session will concentrate on informing participants the importance of having consistency in their physical activity routine and how to access the HIIT workout available to them. The consistency condition will be instructed to complete the provided HIIT workout three times per week. They will be encouraged to complete more than three workouts. The following counseling sessions will be provided to not only continue supporting consistency in physical activity but also to support participants' basic psychological needs.
Study NCT05704907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: gallbladder ultrasound
Description: gallbladder ultrasound
Study NCT06584032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fruquintinib
Description: Fruquintinib will be orally administrated once daily for 2 consecutive weeks followed by a 1-week break.
Study NCT06584032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sintilimab
Description: Sintilimab will be intravenously administrated on Day 1 every three weeks.
Study NCT06584032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175 mg/m\^2 via IV infusion, once a week for 3 weeks followed by a 1-week break.
Study NCT06584032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 60mg/m\^2 via IV infusion, on Day 1 every three weeks.
Study NCT06135636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Direct verbal and written education at the time of enrollment on cocooning and recommendation for partner Tdap vaccination prior to delivery
Study NCT06135636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine administration
Description: Option to receive Tdap at their convenience at the WIH obstetric care clinic provided to participant
Study NCT05511363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KarXT
Description: KarXT 20 mg/2 mg TID KarXT 30 mg/3 mg TID KarXT 40 mg/4 mg TID KarXT 50 mg/5 mg TID KarXT 66.7/6.67 mg TID
Study NCT05511363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Capsules
Study NCT05577377 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orgasmic Meditation
Description: Orgasmic Meditation (OM) is a structured attention training practice that you do with another person by following a predefined set of detailed instructions. One of the two people participating in the OM must have a clitoris. In this partnered practice, one person strokes the clitoris of another person with the tip of their left index finger for 15 minutes.
Study NCT04808947 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia
Description: Procedure: Local infiltration analgesia performed by surgeons.
Study NCT04808947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local infiltration analgesia
Description: Procedure: Local infiltration analgesia performed by surgeons.
Study NCT04808947 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided adductor canal block
Description: Procedure: Ultrasound-guided adductor canal and iPACK blocks performed by anesthesiologists preoperatively.
Study NCT04667520 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity (LPA)
Description: This intervention has 3 components: (1) an orientation session to LPA and using the Fitbit; (2) Six telephone physical activity counseling sessions; and (3) monitoring activity with the Fitbit, which is provided to them during their study participation.
Study NCT04667520 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Only
Description: Participants are provided with a Fitbit during their study participation.
Study NCT05302206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: colonic infusion
Description: colonic glucose or colonic saline infusion
Study NCT06582953 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Turning the Tide Violence Intervention Program (hospital violence intervention program)
Description: TTVIP is already integrated into the regular care of patients who are violently injured and treated at MUSC Charleston. Client advocates provide immediate support, help with communication and provide anti-retaliation messaging to victims of violence and their families, in addition to helping support their healthcare. Patients that opt to be followed for long-term wrap-around services and live in the surrounding 3-county area are supported for months (up to 1 year) after injury and provided mentorship, service referrals (i.e. education, employment, substance abuse, injury recovery, pro-social activities, housing) and mental health services.
Study NCT05907005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT-based EMI
Description: Consists of brief iCBT for psychological support (mandatory), stroke care education (optional), and nurse-led real-time chat-based support messages, delivered according to participants' preferences.
Study NCT05325749 — intervention group
Intervention type: GENETIC
Intervention: Screening
Description: Whole exome sequencing will be done and all infants will receive a report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset diseases for which specific care or prevention protocols are available. Families signed additional informed consent will receive an advanced report including variants with no care or prevention available, mid or low risk variants, and variants with late onset or those suggesting relatives to undergo screening.
Study NCT05325749 — intervention group
Intervention type: GENETIC
Intervention: Family history record
Description: Families enrolled to the study will receive a genetic consult during which a family history will be taken concerning the inherited conditions.
Study NCT05325749 — intervention group
Intervention type: OTHER
Intervention: Questionnaire survey
Description: Families invited to the study will be asked to undergo a questionnaire survey regarding the reasons to accept or refuse the study, the familiarity of the aims, methods and outcomes of the study as well as the satisfaction.
Study NCT05325749 — intervention group
Intervention type: GENETIC
Intervention: Diagnostic
Description: The results of whole exome sequencing will be analysed according to the infant's phenotype in addition the the general screening pipeline
Study NCT05325749 — intervention group
Intervention type: GENETIC
Intervention: Selective screening
Description: The results of whole exome sequencing will be analysed according to the data of prenatal ultrasound examination, family history and other available alarming information in addition the the general screening pipeline
Study NCT05526144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Synthroid
Description: Synthroid tablets 25 mcg. Subjects in the study group will receive Synthroid at a titrated dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for one year duration that will maintain TSH at normal level.
Study NCT05526144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets 25 mcg daily. Subjects in the placebo group will receive placebo tablets at a dose of 25 mcg (one tablet), 50 mcg (two tablets), or maximum of 75 mcg (3 tablets) daily for a one year duration.
Study NCT05685563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DIERS formetic 4D
Description: Assessment of mentioned tests and their comparison.
Study NCT06142396 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Daratumumab-hyaluronidase in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone
Description: This intervention is Daratumumab-hyaluronidase in combination with the chemotherapy regimen CyBord (cyclophosphamide, bortezomib, and dexamethasone) and then with lenalidomide maintenance in patients with newly diagnosed multiple myeloma who have new onset renal failure.
Study NCT05006404 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonary Valve Replacement Surgery
Description: Pulmonary valve replacement surgery with the Autus Valve
Study NCT06567886 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light Therapy
Description: Participants will self-administer the daily light therapy within a few minutes of their assigned wake up time for one hour.~Researchers will provide a light log to note light on/off times, any interruptions to light therapy, and primary activity during light therapy.
Study NCT06272279 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spinal stimulation-DCS
Description: transcutaneous spinal stimulation by direct current stimulation
Study NCT06272279 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: spinal stimulation-sham DCS
Description: sham transcutaneous spinal stimulation by direct current stimulation
Study NCT06272279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal stimulation-EPS
Description: transcutaneous spinal stimulation by electrical pulsed stimulation
Study NCT06272279 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham spinal stimulation-EPS
Description: sham transcutaneous spinal stimulation by electrical pulsed stimulation
Study NCT06567886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Stabilization
Description: All participants will be asked to follow a fixed sleep schedule.
Study NCT05745506 — intervention group
Intervention type: OTHER
Description: Not applicable, there is no intervention description in this study.
Study NCT05734703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutraceutical Topical
Description: Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
Study NCT02615808 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen saturation data visualization
Description: The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
Study NCT05746572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Participants will receive MDMA HCl (100 mg, 84 mg MDMA) in combination with massed exposure therapy for PTSD.
Study NCT05421585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: observational drug study
Description: Postoperative opioid consumption will be evaluated by applying 2 different block methods to patients who have undergone lumbar disc surgery
Study NCT06339281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib mesylate+Capecitabine Tablets
Description: Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Capecitabine Tablets: 1000 mg/m2, po, twice a day, d1-d14, discontinued for 1 week after 2 weeks of treatment;
Study NCT06339281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: apatinib mesylate+Fulvestrant injection
Description: Apatinib Mesylate Tablets: 500 mg, qd, orally until disease progression or intolerable adverse reactions.~Fulvestrant injection 500 mg, intramuscular injection, q4w, once on d1 and d15 in the first cycle;
Study NCT06065241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LLP-01
Description: Participants in the experimental group will take 2 capsules daily containing 1,000mg of the formulation, LLP-01, for 60 days.
Study NCT06065241 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo group will take 2 capsules daily containing rice flower and small amount of Curcuma Longa for 60 days.
Study NCT05790967 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Education
Description: Women in the experimental group will be given education on sexual life during pregnancy. Before the training, preliminary data will be collected and then the participants will be given two hours of individual and face-to-face training.
Study NCT06339502 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jigsaw Technique
Description: The jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
Study NCT06281119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervavac as three dose regimen
Description: Cervavac manufactured by Serum Institute of India Pvt Ltd administered as three doses at day 0, 60 and 180.
Study NCT06281119 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervavac as two dose regimen
Description: Cervavac manufactured by Serum Institute of India Pvt Ltd administered as two doses at day 0 and 180.
Study NCT06281119 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil as three dose regimen
Description: Gardasil manufactured by MSD administered as a three doses at day 0,60 and 180.
Study NCT06315439 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound fine needle biopsy
Description: EUS FNA/B for solid pancreatic lesions. After the FNA/FNB, the needle was removed from the EUS endoscope and the specimen obtained after the first needle pass was expelled and placed directly in a dedicated scaffold (Cytomatrix, UCS Diagnostics).~a drop of ethanol was put on it and the liquid was drained away thanks to the porous structure of the matrix. This step was followed by the deposition of a drop of acridine-orange for 20 and a rapid washing with buffered saline. After that, the Cytomatrix was put on a dedicated microscopic slide and covered with a second slide before the introduction in the slot of the machine.~The FCM VivaScope® 2500 (2500M-G4; VivaScope, Munich, Germany) was used for immediate imaging.
Study NCT05488405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine Oral Product
Description: Mesalamine oral suspension for oral use
Study NCT05226325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patients will receive after induction of anesthesia DEX at 1 mcg/kg for 10 minute followed by infusion
Study NCT04192357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WLM3P
Description: 18 months behavioral weight loss program divided into three phases (first and second phase of weight loss, during 1 month and 5 months, respectively; and a third phase of weight maintenance, during 12 months).
Study NCT04192357 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-carb diet
Description: 18 months behavioral weight loss program divided in two phases (first of weight loss during 6 months and a second phase of weight maintenance during 12 months).
Study NCT05153681 — intervention group
Intervention type: OTHER
Intervention: Peloid Therapy
Description: Peloid therapy; A total of 10 sessions were applied for 30 minutes by heating the proximal part of the sole of the foot, including the heel part, at a temperature of 45 degrees. Kinesioband application: One strip is prepared as a rake with a length of about 25 cm, and the other strip is prepared as an I tape with a length of about 20 cm. The ankle is in a neutral position of 90 degrees. Lymphatic and mechanical correction technique is applied. Afterwards, the band is activated.
Study NCT05175768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Mononucleotide
Description: Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
Study NCT05175768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide Mononucleotide with L-Leucine
Description: Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
Study NCT05175768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sachets to be taken orally after breakfast and Two sachets after lunch with water.
Study NCT04727554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 994
Description: Administered as an intravenous (IV) infusion.
Study NCT04727554 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 404
Description: Administered as an intravenous (IV) infusion.
Study NCT06470568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Resistance exercise training
Description: The training sessions will begin with a 5-minute warm-up on a cycle ergometer and global movements involving the upper limbs. Following this, participants will perform one additional warm-up set, followed by four regular sets on both the leg press and leg extension machines. Upper body exercises will then be conducted on the chest press, pull-up, and horizontal rowing machines, with each exercise comprising 2 sets.~To conclude each session, there will be a 5-minute cooldown period involving global muscle stretching exercises. During the initial 6-week period, the workload will progressively increase from 60% to 80% of 1RM (10 repetitions per set). Subsequently, the 1RM will be reassessed to adjust workloads (maintaining 60%-80%) for the subsequent 6-week period. Compliance for per-protocol analysis will require participants to complete at least 80% of the training sessions (i.e., a minimum of 29 out of 36 sessions).
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Giredestrant
Description: 30 milligrams (mg) orally once a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression
Study NCT04802759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg orally twice a day (during each 28-day cycle or 21-day cycle, depending on the regimen) until unacceptable toxicity or disease progression